Global Montelukast Sodium Market Insights Forecasts to 2033.

• The Global Montelukast Sodium Market Size was Valued at USD 4.1 Billion in 2023.
• The Market Size is Growing at a CAGR of 5.64% from 2023 to 2033.
• The Worldwide Montelukast Sodium Market Size is Expected to Reach USD 7.1 Billion by 2033.
• Asia Pacific is expected to Grow the fastest during the forecast period.

The Global Montelukast Sodium Market Size is Anticipated to Exceed USD 7.1 Billion by 2033, Growing at a CAGR of 5.64% from 2023 to 2033.

Market Overview

Montelukast sodium is a leukotriene inhibitor that is frequently sold under the brand name Singulair. It is used to treat asthma-related side effects, including dyspnea. In addition to treating asthma, it also treats a number of fungal and allergy illnesses. It is also used as a pre-workout before engaging in physical activity to prevent respiratory complications. Doctors frequently prescribe montelukast oral granule pills to treat fungal or allergy infections. The use of these medications is increasing as the prevalence of respiratory conditions, including pneumonia, lung infections, COPD, asthma, and emphysema, increases as a result of skyrocketing pollution, which is also encouraging teen smoking. Spreading infections as the elderly population rises in both developed and developing nations after COVID-19 are expected to fuel the expansion of the global montelukast sodium market. In addition, the production of montelukast API via intense and continuous research and development efforts by major industry players is one of the key factors that are currently driving this market.

Report Coverage

This research report categorizes the market for the global montelukast sodium market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global montelukast sodium market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global montelukast sodium market.

Driving factor

The global montelukast sodium market is driven by various factors, including the rise in the prevalence of chronic respiratory conditions like asthma worldwide. With asthma thought to be the most prevalent chronic illness worldwide, there has been a big need for novel therapies. Severe asthma can be a debilitating condition that requires asthma medication. Because of this, it is anticipated that the growing need for those with asthma to lead better lives will help the market grow. The American Academy of Asthma, Allergy, and Immunology estimated that 8.3% of children in the US will suffer from asthma. During the projected period, the development of affordable and efficient therapies will propel market expansion. In addition, asthma and other bronchial problems can occur in susceptible individuals when the air quality exceeds 101, according to the WHO. After this, countries with high AQI, such as China and India, have risen to the top and will help the market grow.

Restraining Factors

The leukotriene inhibitor Montelukast sodium has a number of adverse health effects that contribute to the market's continuous growth. Sleepiness, nausea, diarrhea, looseness, gastrointestinal distress, and respiratory problems like congestion, coughing, and sore throats are a few side effects. These issues have the potential to hamper Montelukast's industry.

Market Segmentation

The Global Montelukast Sodium Market share is classified into dosage form and application.

• The simple pills segment is expected to hold the largest share of the global montelukast sodium market during the forecast period.   

Based on the dosage form, the global montelukast sodium market is divided into tablets, oral solutions simple pills, chewable pills, powder, and others. Among these, the simple pills segment is expected to hold the largest share of the global montelukast sodium market during the forecast period. The reasons for this growth are as follows: the geriatric population is the most commonly consumed this form of medication, so demand for it is growing; pills have high accuracy because they are properly coated to protect them from environmental factors like air and moisture; bulk production is possible; and production costs are low for the companies.

• The asthma segment is expected to hold the largest share of the global montelukast sodium market during the forecast period.   

Based on the application, the global montelukast sodium market is divided into asthma, allergic rhinitis, urticaria, and others. Among these, the asthma segment is expected to hold the largest share of the global montelukast sodium market during the forecast period. Global asthma prevalence is rising, which is driving market expansion. For instance, the Centers for Disease Control and Prevalence estimate that in 2022, 8.7% of individuals over the age of 18 and 6.2% of children under the age of 18 had asthma. Approximately 939,000 individuals with asthma stay in an urgent care center each year. It is thus anticipated that the market is going to grow.

Regional Segment Analysis of the Global Montelukast Sodium Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global montelukast sodium market over the predicted timeframe.

North America is anticipated to hold the largest share of the global montelukast sodium market over the predicted timeframe. The growing number of cases of breathing irregularities among adults and teens as a result of smoking, as well as bad eating habits that contribute to disorders like obesity are some of the causes driving this segment's rise. However, the widespread availability of different retail pharmacies and drug stores, along with a well-established healthcare system, are pushing the total medication use. Roughly one in thirteen Americans, or 25 million people, has had asthma.

Asia Pacific is expected to grow the fastest during the forecast period. This increase is triggered by an aging population that is becoming more prevalent, particularly in China and India, which are the two nations that release the most carbon dioxide, aggravating conditions like asthma. However, as these countries' GDPs are growing, they can afford to invest more on research and development.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global montelukast sodium along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Cipla
• Merck & Co.
• Hetero Labs
• Ortin laboratories
• Mylan N.V
• Morepen laboratories
• Teva Pharmaceuticals
• MSN Laboratories
• Vamsi Labs
• Medopharm
• Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2021, the US Health Department gave the pharmaceutical company Morepen Laboratories permission to sell its generic anti-allergy medication, felofenadine hydrochloride, on the US market.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Montelukast Sodium Market based on the below-mentioned segments: 

Global Montelukast Sodium Market, By Dosage Form

• Tablets
• Oral Solutions
• Simple Pills
• Chewable Pills
• Powder
• Others

Global Montelukast Sodium Market, By Application

• Asthma
• Allergic Rhinitis
• Urticaria
• Other

Global Montelukast Sodium Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa